order
mononegaviral
compris
nonseg
neg
sens
singlestrand
rna
virus
famili
filovirida
along
famili
rhabdovirida
paramyxovirida
bornavirida
famili
filovirida
contain
two
genera
ebolaviru
ebov
marburgviru
marv
infect
ebov
marv
caus
sever
often
fatal
hemorrhag
fever
hf
case
fatal
rate
rang
depend
strain
andor
speci
ebolaviru
genu
divers
consist
four
speci
sudan
ebolaviru
sebov
zair
ebolaviru
zebov
cote
divoir
ebolaviru
ciebov
reston
ebolaviru
rebov
put
fifth
speci
bundibugyo
ebolaviru
bebov
discov
outbreak
uganda
togeth
ebolaviru
genu
account
least
outbreak
date
back
occur
within
last
year
marburgviru
genu
one
speci
lake
victoria
marburgviru
respons
least
nine
outbreak
sinc
five
occur
last
decad
increas
frequenc
ebov
marv
outbreak
along
fact
virus
potenti
agent
bioterror
increas
public
health
concern
regard
filovirus
present
licens
vaccin
postexposur
treatment
avail
human
use
howev
least
six
differ
vaccin
candid
shown
potenti
protect
nonhuman
primat
nhp
lethal
ebov
andor
marv
infect
filovirus
contain
rna
genom
approxim
kb
length
encod
seven
protein
arrang
nucleoprotein
np
virion
protein
vp
glycoprotein
gp
polymeras
protein
l
ebov
speci
express
two
extra
nonstructur
protein
gp
gene
refer
solubl
gp
small
solubl
ss
gp
vaccin
studi
shown
protect
anim
filoviru
infect
primarili
employ
gp
protein
immunogen
studi
also
use
andor
np
vesicular
stomat
viru
vsv
member
famili
rhabdovirida
compos
genom
approxim
kb
encod
five
protein
arrang
nucleoprotein
n
phosphoprotein
p
matrix
protein
glycoprotein
g
larg
catalyt
subunit
l
rnadepend
rna
polymeras
last
decad
use
recombin
r
vsv
vaccin
candid
studi
due
abil
insert
express
foreign
gene
simpl
genom
abil
propag
viru
high
titer
mammalian
cell
line
lack
recombin
insert
host
cell
genom
extrem
low
percentag
vsv
seroposit
gener
popul
central
america
minim
pathogen
vsv
human
rvsv
vector
develop
vaccin
candid
mani
import
human
pathogen
influenza
viru
human
immunodefici
viru
hiv
measl
viru
respiratori
syncyti
viru
papillomaviru
sever
acut
respiratori
syndrom
coronaviru
hf
virus
lassa
ebov
marv
rvsv
filoviru
gp
vaccin
platform
vsv
glycoprotein
g
replac
filoviru
gp
shown
promis
singleinject
prevent
vaccin
postexposur
treatment
ebov
andor
marv
challeng
nhp
initi
studi
show
singl
intramuscular
im
vaccin
cynomolgu
macaqu
rvsv
vector
express
zebov
gp
marv
gp
induc
strong
humor
andor
cellular
immun
respons
elicit
complet
protect
high
dose
plaqu
form
unit
pfu
im
challeng
homolog
zebov
marv
given
day
later
efficaci
vaccin
protect
im
vaccin
homolog
high
dose
pfu
aerosol
challeng
also
test
importantli
homolog
aerosol
challeng
either
zebov
marv
day
vaccin
result
complet
protect
macaqu
addit
vaccin
via
im
rout
abil
rvsvzebovgp
vaccin
protect
cynomolgu
macaqu
intranas
oral
rout
also
studi
vaccin
differ
rout
result
complet
protect
homolog
challeng
elicit
robust
zebov
gpspecif
humor
respons
tcell
respons
induc
vaccin
also
month
zebov
challeng
recent
show
singl
inject
blend
vaccin
consist
equal
part
rvsvzebovgp
rvsvsebovgp
rvsvmarvgp
complet
protect
nhp
lethal
challeng
either
zebov
sebov
ciebov
marv
rvsv
filoviru
gp
vector
proven
robust
prevent
vaccin
vector
also
shown
util
postexposur
treatment
rvsvmarvgp
vector
protect
rhesu
macaqu
challeng
marv
treat
minut
hour
hour
postexposur
respect
treatment
macaqu
minut
challeng
rvsvsebov
gp
vector
protect
anim
lethal
sebov
challeng
treatment
macaqu
minut
challeng
rvsvzebov
gp
vector
protect
anim
homolog
zebov
challeng
date
rvsv
filoviru
gp
vector
use
nhp
sign
toxic
result
vaccin
addit
rvsvzebovgp
vector
recent
use
treatment
less
hour
possibl
accident
zebov
exposur
laboratori
worker
germani
efficaci
treatment
conclus
treat
individu
experienc
mild
fever
myalgia
headach
hour
inject
although
data
suggest
vector
innocu
use
rvsv
filoviru
gp
vector
vaccin
andor
postexposur
treatment
human
requir
safeti
test
import
consid
vaccin
replicationcompet
potenti
vsv
neurovirul
nv
report
rodent
macaqu
cattl
sheep
hors
regardless
potenti
rvsv
vector
nv
replicationcompet
vaccin
use
human
gener
subject
nv
test
typic
nv
evalu
direct
inocul
vaccin
central
nervou
system
cn
nhp
nv
test
develop
measl
viru
mump
viru
yellow
fever
viru
polioviru
recent
rvsv
hiv
vaccin
variant
test
nv
intrathalam
inocul
promis
result
current
studi
evalu
nv
potenti
rvsvzebovgp
rvsvmarvgp
vector
cynomolgu
macaqu
nv
test
model
previou
examin
yellow
fever
viru
vaccin
rvsv
hiv
vector
variant
cynomolgu
macaqu
given
inocul
pfu
vaccin
close
monitor
cours
day
rvsvwt
fig
use
studi
recov
cdna
use
method
previous
describ
rvsv
filoviru
gp
vector
rvsvzebovgp
fig
rvsvmarvgp
fig
recov
cdna
previous
describ
virus
propag
infect
vero
cell
multipl
infect
collect
supernat
cell
show
cytopath
effect
media
use
propag
rvsv
consist
dulbecco
modifi
essenti
media
heatinactiv
certifi
fb
invitrogen
carlsbad
ca
penicillinstreptomycin
invitrogen
glutamax
invitrogen
viru
supernat
mockinfect
cell
supernat
vehicl
control
clarifi
cell
debri
aliquot
use
studi
titer
determin
vero
cell
monolay
convent
plaqu
assay
rvsv
prepar
assess
presenc
endotoxin
use
test
system
pt
charl
river
wilmington
viru
prepar
dilut
limulu
amebocyt
lysat
lal
reagent
water
lrw
per
manufactur
direct
endotoxin
level
test
lal
cartridg
direct
manufactur
viru
prepar
found
detect
limit
posit
control
show
test
valid
total
healthi
male
cynomolgu
macaqu
macaca
fasciculari
kg
purchas
charl
river
laboratori
wilmington
anim
rang
age
year
except
two
anim
year
age
studi
conduct
new
england
primat
research
center
neprc
harvard
medic
school
anim
given
care
accord
standard
associ
assess
accredit
laboratori
anim
care
harvard
medic
school
anim
care
use
committe
anim
work
adher
regul
outlin
usda
anim
welfar
act
cfr
part
condit
specifi
guid
care
use
laboratori
anim
ilar
public
nation
academi
press
harvard
medic
school
anim
care
use
committe
experi
procedur
approv
harvard
medic
area
stand
committe
anim
clinic
sign
ill
distress
promptli
report
respons
veterinarian
recommend
treatment
minor
ailment
euthanasia
clinic
observ
neurolog
score
anim
reach
level
base
approv
harvard
medic
school
anim
care
use
committe
protocol
anim
sedat
ketamin
hcl
administ
im
intub
place
saphen
cathet
place
nacl
infus
mlhr
atropin
buprenex
cephazolin
administ
im
anim
head
shave
surgic
prepar
midlin
incis
made
along
scalp
skin
musculatur
retract
two
cm
hole
one
per
side
correspond
posit
incis
left
right
side
made
skull
use
high
speed
gener
twist
drill
steril
salin
use
flush
clear
boni
debri
drill
inoculum
administ
use
gaug
inch
needl
thalam
region
anim
receiv
one
four
possibl
inocul
three
primari
inocul
consist
pfu
either
rvsvwt
n
rvsvzebovgp
n
rvsvmarvgp
n
heatinactiv
fetal
bovin
serum
fb
dulbecco
modifi
eagl
media
vehicl
control
n
consist
clarifi
vero
cell
cultur
supernat
heatinactiv
fb
dulbecco
modifi
eagl
media
small
piec
gel
foam
place
burr
hole
direct
pressur
use
achiev
hemostasi
musculatur
skin
close
simpl
interrupt
pattern
cephazolin
administ
day
buprenex
administ
hour
post
procedur
longer
necessari
anim
monitor
daili
veterinari
anim
care
staff
anim
given
thorough
physic
examin
time
schedul
phlebotomi
blood
phlebotomi
monitor
hematolog
whole
blood
clinic
chemistri
serum
daili
cage
side
neurolog
exam
conduct
anim
receiv
overal
impair
score
character
neurolog
base
specif
observ
point
list
clinic
sign
enceph
rough
coat
eat
high
pitch
vocal
inact
slow
move
shaki
movement
tremor
incoordin
limb
weak
inabl
stand
limb
paralysi
moribund
total
white
blood
cell
count
white
blood
cell
differenti
red
blood
cell
count
platelet
count
hematocrit
valu
mean
cell
volum
mean
corpuscular
volum
mean
corpuscular
hemoglobin
concentr
determin
blood
sampl
collect
tube
contain
edta
use
laserbas
hematolog
analyz
hemavet
drew
scientif
waterburi
ct
concentr
albumin
amylas
globulin
alanin
aminotransferas
aspart
aminotransferas
alkalin
phosphatas
gammaglutamyltransferas
lactat
dehydrogenas
glucos
cholesterol
total
protein
total
bilirubin
direct
bilirubin
urea
nitrogen
creatinin
creatinin
kinas
triglycerid
bicarbon
calcium
phosphoru
chlorid
potassium
sodium
measur
idexx
vetconnect
westbrook
use
olympu
biochemistri
analyz
olympu
america
center
valley
pa
anim
euthan
neurolog
sign
develop
schedul
studi
endpoint
day
post
inocul
overdos
intraven
sodium
pentobarbit
necropsi
immedi
afterward
tissu
five
brain
region
frontal
cortex
fc
occipit
cortex
oc
cerebellum
cb
thalamu
th
basal
ganglia
bg
three
spinal
cord
sc
region
cervic
thorac
lumbar
collect
neutralbuff
formalin
follow
one
week
fixat
brain
hemisect
right
left
hemispher
specifi
brain
region
trim
embed
paraffin
section
stain
use
hematoxylin
eosin
h
e
h
e
stain
section
brain
spinal
cord
analyz
histopatholog
chang
associ
nv
anim
section
fc
bg
oc
th
cb
brain
stem
bs
sc
analyz
histopatholog
chang
consist
nv
doubleblind
score
base
presenc
sever
perivascular
infiltr
gliosi
neurodegener
satellitosi
necrosi
cumul
assess
chang
score
sever
scale
base
previous
publish
work
lesion
minim
perivascular
inflammatori
infiltr
gliosi
neurodegener
satellitosi
necrosi
mild
perivascular
inflammatori
infiltr
mild
gliosi
neurodegener
satellitosi
necrosi
moder
inflammatori
infiltr
moder
gliosi
mild
neurodegener
mild
satellitosi
mild
necrosi
sever
inflammatori
infiltr
moder
sever
gliosi
neurodegener
satellitosi
necrosi
score
brain
region
deriv
right
left
hemispher
also
combin
total
nv
score
sc
section
collect
repres
singl
number
statist
calcul
histolog
score
use
graphpad
prism
softwar
use
unpair
twotail
test
assess
viral
load
nasal
oral
rectal
swab
day
blood
day
tissu
spleen
liver
kidney
heart
axillari
lymph
node
adren
gland
neural
tissu
fc
bg
oc
th
cb
bs
sc
rna
extract
swab
viru
rna
kit
qiagen
valencia
ca
tissu
section
rneasi
kit
qiagen
taqman
pcr
rvsv
genom
perform
rvsv
taqman
assay
detect
vsv
genom
antigenom
develop
use
primer
probe
target
intergen
region
g
vsv
genom
gene
previous
describ
rvsv
probe
primer
appli
biosystem
carlsbad
ca
sequenc
ttggcctgattgtcg
carboxytetramethylrhodamin
tamra
onestep
realtim
pcr
rtpcr
done
use
onestep
rtpcr
kit
qiagen
rtpcr
mixtur
contain
rna
eluat
master
mix
set
follow
manufactur
protocol
standard
test
sampl
assay
triplic
use
detect
system
biorad
laboratori
hercul
ca
follow
cycl
condit
min
min
cycl
threshold
cycl
ct
valu
repres
rvsv
genom
antigenom
analyz
cfx
manag
softwar
data
shown
genom
equival
geq
creat
geq
standard
rna
rvsvwt
stock
extract
number
rvsv
genom
calcul
use
avogadro
number
molecular
weight
rvsv
genom
assess
replic
viru
nasal
oral
rectal
swab
day
blood
day
nonneur
tissu
spleen
liver
kidney
heart
axillari
lymph
node
adren
gland
neural
tissu
fc
bg
oc
th
cb
bs
sc
viru
titer
determin
convent
plaqu
assay
vero
cell
monolay
swab
collect
place
media
tissu
place
media
homogen
plaqu
assay
order
evalu
nv
potenti
rvsv
filoviru
gp
vector
cynomolgu
macaqu
inocul
inocul
pfu
either
rvsvzebovgp
n
fig
rvsvmarvgp
n
fig
rvsvwt
n
fig
vehicl
control
n
anim
receiv
two
inocul
one
per
hemispher
left
hemispher
receiv
experiment
inocul
right
hemispher
receiv
vehicl
control
anim
observ
neurolog
sign
diseas
clinic
two
macaqu
rvsvwt
control
group
develop
progress
neurolog
sign
includ
ataxia
propriocept
deficit
tremor
euthan
either
day
post
inocul
tabl
one
rvsvwt
anim
show
discern
neurolog
sign
neurolog
deficit
observ
macaqu
vehicl
control
rvsvzebovgp
rvsvmarvgp
group
hematolog
serum
biochemistri
also
monitor
anim
chang
observ
anim
compar
preble
anim
cours
studi
data
shown
swab
blood
collect
day
studi
fig
tissu
collect
necropsi
prepar
viru
rna
isol
detect
rvsv
plaqu
assay
rvsv
genom
antigenom
rna
taqman
quantit
realtim
qrt
pcr
indic
rvsv
replic
two
rvsvwt
macaqu
show
clinic
sign
neurolog
diseas
tabl
also
rvsv
rvsv
genom
frontal
cortex
section
one
anim
rvsv
rvsv
genom
left
right
hemispher
frontal
cortex
section
tabl
one
anim
rvsvzebovgp
group
low
level
rvsv
rna
detect
day
post
inocul
viru
isol
tissu
tabl
anim
rvsvmarvgp
group
low
level
detect
rvsv
rna
axillari
lymph
node
ln
taken
day
post
inocul
viru
isol
tissu
tabl
none
macaqu
detect
rvsv
rna
neural
tissu
spleen
liver
heart
kidney
axillari
ln
adren
gland
data
shown
nonneur
neg
tissu
three
anim
rvsvzebovgp
group
also
detect
rvsv
rna
nasal
oral
rectal
swab
differ
time
post
inocul
viru
isol
nasal
swab
day
post
inocul
tabl
none
anim
detect
level
rvsv
rna
blood
sampl
taken
data
shown
four
macaqu
receiv
vehicl
control
hemispher
inflammatori
lesion
brain
spinal
cord
section
fig
tabl
examin
except
one
section
one
anim
singl
mening
parenchym
perivascular
cuff
lymphocyt
right
thalamu
near
vehicl
control
inocul
site
tabl
three
macaqu
receiv
rvsvwt
profound
histolog
lesion
tabl
lesion
pronounc
cortic
basal
ganglia
lesion
lesser
sever
encount
caudal
brainstem
cerebellum
lesion
consist
mark
perivascular
cuff
parenchym
aggreg
lymphocyt
macrophag
fewer
plasma
cell
fig
arrow
panel
e
f
lymphocyt
often
replac
lost
neuron
scatter
neuron
satellitosi
necrosi
degener
gliosi
mark
region
intens
inflamm
overli
mening
typic
contain
small
moder
number
lymphocyt
macrophag
fig
panel
f
spinal
cord
section
three
anim
display
similar
lesion
howev
lesion
one
anim
milder
minim
inflamm
scatter
neuron
satellitosi
tabl
seven
anim
receiv
rvsvzebovgp
varieti
mild
histolog
chang
one
anim
lack
parenchym
lesion
brain
spinal
cord
tabl
anim
rare
focal
area
mening
inflamm
variou
cerebr
section
fig
tabl
one
anim
small
focal
area
mening
inflamm
cerebellum
spinal
cord
lesion
rvsvzebovgp
anim
examin
fig
tabl
macaqu
receiv
rvsvmarvgp
inocul
vari
histolog
two
anim
histolog
lesion
present
brain
spinal
cord
section
examin
tabl
two
differ
anim
mild
lesion
cortex
consist
small
perivascular
cuff
lymphocyt
rare
macrophag
tabl
anoth
anim
similar
perivascular
infiltr
also
present
brainstem
tabl
multifoc
mening
perivascular
aggreg
lymphocyt
also
seen
two
anim
fig
lastli
one
anim
focal
tract
necrosi
caudal
basal
gangliaproxim
thalamu
correspond
inject
site
brain
lesion
observ
away
inject
site
rvsvmarvgp
anim
tabl
figur
repres
averag
combin
left
right
hemispher
score
tabl
group
studi
order
compar
combin
histolog
score
neural
tissu
overal
comparison
rvsvwt
group
rvsvzebovgp
rvsvmarvgp
group
show
differ
score
signific
p
p
respect
data
rvsv
filoviru
gp
vaccin
appear
substanti
nv
cynomolgu
macaqu
seven
year
ago
rvsv
vector
express
foreign
gp
ebov
marv
develop
character
rvsv
vaccin
vector
subsequ
use
cynomolgu
rhesu
macaqu
assess
abil
protect
anim
lethal
challeng
zebov
sebov
ciebov
marv
respect
result
initi
experi
promis
vsv
rvsv
display
nv
experiment
set
use
rodent
cynomolgu
rhesu
macaqu
inocul
intracerebr
nv
seen
experiment
set
rais
question
safeti
nv
replicationcompet
rvsv
filoviru
gp
vaccin
address
question
compar
vehicl
control
rvsvwt
rvsvzebovgp
rvsvmarvgp
sinc
vaccin
vector
replicationcompet
model
nv
test
platform
score
system
employ
yellow
fever
viru
vaccin
rvsv
hiv
vaccin
vector
contrari
rvsvwt
cohort
none
macaqu
either
vehicl
control
group
two
filoviru
vaccin
group
display
clinic
neurolog
abnorm
tabl
pattern
also
seen
compar
amount
detect
rvsv
rna
macaqu
two
rvsvwt
anim
signific
amount
rvsv
rvsv
rna
detect
neural
tissu
tabl
particular
interest
one
anim
also
rvsv
rvsv
rna
detect
right
frontal
cortex
consid
experiment
inocul
left
hemispher
thalamu
suggest
spread
rvsvwt
neural
tissu
histopatholog
analysi
confirm
rvsvwt
viru
nv
cynomolgu
macaqu
caus
sever
enceph
inocul
three
anim
cohort
display
vari
degre
inflamm
neurodegener
brain
spinal
cord
section
evalu
one
macaqu
sever
score
throughout
neural
tissu
tabl
correl
detect
amount
rvsv
rna
neural
tissu
tabl
none
anim
rvsv
filoviru
gp
vaccin
vehicl
control
group
show
evid
neurodegener
neuroinflamm
anim
rvsv
filoviru
gp
vaccin
group
occasion
perivascular
lymphocyt
mening
infiltr
primarili
frontal
cortex
thalamu
fig
tabl
howev
spread
adjac
parenchyma
evid
neurodegener
satellitosi
gliosi
also
interest
note
lesion
seen
spinal
cord
two
rvsv
filoviru
gp
vaccin
group
wherea
lesion
seen
rvsv
hiv
vaccin
itinocul
macaqu
previou
studi
differ
lesion
seen
rvsv
hiv
vaccin
itinocul
macaqu
studi
could
fact
hiv
vaccin
still
contain
vsv
g
protein
wherea
rvsv
filoviru
gp
vaccin
lack
vsv
g
protein
also
describ
johnson
et
al
observ
could
result
contamin
cerebrospin
fluid
perform
inocul
could
case
although
observ
lesion
spinal
cord
macaqu
rvsvwt
group
includ
one
anim
show
major
clinic
neurolog
diseas
symptom
detect
rvsv
rna
day
neural
tissu
taken
togeth
histolog
lesion
score
confirm
neither
rvsvzebovgp
rvsvmarvgp
significantli
nv
neither
caus
signific
neuropatholog
cynomolgu
macaqu
inocul
compar
clarifi
vero
cell
cultur
fluid
rvsvwt
interest
note
mild
inflamm
seen
vaccin
cohort
studi
far
deem
accept
mump
vaccin
mani
countri
recent
review
although
neurotrop
differ
virus
difficult
compar
find
rvsv
filoviru
gp
vaccin
similar
even
attenu
nv
wide
use
vaccin
encourag
recoveri
detect
rvsv
rna
swab
seem
correl
small
lesion
seen
rvsvzebovgp
anim
small
lesion
mening
cerebellum
small
lesion
mening
right
basal
ganglia
wherea
one
anim
detect
lesion
tabl
low
amount
rvsv
rna
detect
left
frontal
cortex
one
anim
despit
detect
rvsv
rna
site
spinal
cord
lesion
anim
neural
tissu
sampl
anim
observ
combin
swab
data
anim
suggest
rvsvzebovgp
viru
may
move
beyond
neural
tissu
site
inocul
thought
interest
consid
ebov
marv
initi
target
dendrit
cell
macrophag
vivo
fact
rvsv
vector
express
filoviru
gp
protein
virion
surfac
would
target
vector
dendrit
cell
macrophag
could
explain
case
detect
area
outsid
neural
tissu
perhap
target
dendrit
cell
macrophag
appear
inocul
site
migrat
ln
tabl
site
tabl
rna
abl
isol
fact
day
nasal
swab
posit
viru
isol
tabl
low
level
viru
consid
lack
shed
vaccin
previou
studi
interest
possibl
viru
may
detect
studi
transfer
viru
along
neuron
olfactori
bulb
olfactori
neuron
fact
nasal
swab
procedur
sometim
result
minor
bleed
regardless
gentl
nare
swab
could
pick
low
level
viremia
pick
qrtpcr
lack
nv
rvsv
filoviru
gp
vaccin
vector
compar
rvsvwt
encourag
consid
vaccin
attenu
mutat
known
virul
marker
methionin
vsv
protein
result
similar
studi
vsv
vector
express
influenza
hemagglutinin
ha
protein
complet
attenu
pathogenesi
mous
model
compar
rvsvwt
studi
result
perhap
surpris
consid
glycoprotein
viru
gener
contribut
cell
tropism
compar
vsv
filovirus
influenza
viru
show
neural
tropism
delet
vsv
g
replac
protein
glycoprotein
foreign
virus
neural
tropism
would
suggest
rvsv
foreign
glycoprotein
would
nv
howev
even
though
glycoprotein
contribut
cell
tropism
viral
factor
also
contribut
rule
nv
test
import
evalu
vaccin
safeti
clinic
histolog
viru
replic
data
studi
indic
rvsvzebovgp
rvsvmarvgp
vector
lack
nv
properti
rvsvwt
vector
addit
nv
studi
rvsvzebovgp
vector
safeti
test
two
anim
model
defect
immun
system
nodscid
mice
shivinfect
rhesu
monkey
upon
immun
evid
overt
ill
note
immunocompromis
anim
also
rvsvzebovgp
vector
recent
use
treat
laboratori
worker
recent
laboratori
accid
without
major
complic
previous
shown
rvsv
filoviru
gp
vector
efficaci
prevent
vaccin
postexposur
treatment
promis
safeti
profil
data
togeth
find
current
nv
studi
suggest
rvsv
filoviru
gp
vaccin
system
readi
advanc
develop
human
use
